BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 7536126)

  • 1. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation.
    Critz FA; Tarlton RS; Holladay DA
    Cancer; 1995 May; 75(9):2383-91. PubMed ID: 7536126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.
    Critz FA; Levinson AK; Williams WH; Holladay DA
    J Clin Oncol; 1996 Nov; 14(11):2893-900. PubMed ID: 8918485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
    Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
    Ragde H; Elgamal AA; Snow PB; Brandt J; Bartolucci AA; Nadir BS; Korb LJ
    Cancer; 1998 Sep; 83(5):989-1001. PubMed ID: 9731904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation.
    Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
    Cancer J Sci Am; 1998; 4(6):359-63. PubMed ID: 9853134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate brachytherapy: treatment strategies.
    Stone NN; Stock RG
    J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
    Zagars GK
    J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term follow-up of serum prostate-specific antigen after radiotherapy of prostatic carcinoma].
    Schmid HP; Ferrari MK; Stamey TA
    Helv Chir Acta; 1994 Dec; 60(6):1101-5. PubMed ID: 7533148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
    Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
    J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma.
    Ragde H; Blasko JC; Grimm PD; Kenny GM; Sylvester JE; Hoak DC; Landin K; Cavanagh W
    Cancer; 1997 Aug; 80(3):442-53. PubMed ID: 9241078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
    Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
    Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques.
    Critz FA; Williams WH; Levinson AK; Benton JB; Holladay CT; Schnell FJ
    J Urol; 2000 Sep; 164(3 Pt 1):738-41; discussion 741-3. PubMed ID: 10953137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer.
    Critz FA; Levinson K; Williams WH; Holladay D; Holladay C; Griffin V
    Urology; 1997 May; 49(5):668-72. PubMed ID: 9145968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy.
    Borghede G; Aldenborg F; Wurzinger E; Johansson KA; Hedelin H
    Br J Urol; 1997 Aug; 80(2):247-55. PubMed ID: 9284197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
    Aref I; Eapen L; Agboola O; Cross P
    Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up.
    Medini E; Medini I; Reddy PK; Levitt SH
    Cancer; 1996 Sep; 78(6):1254-9. PubMed ID: 8826948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.